Ocular delivery systems for the administration of antibody therapeutics

Su Eon Jin, Sung Joo Hwang

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Antibodies (Abs) have been extensively used as a powerful tool for targeting proteins based on their immunologic functions such as antigen recognition and pathogen neutralization. In particular, monoclonal Abs (mAbs) and fragments can be promising drugs in clinics owing to their sensitivity and specificity. The controlled release of Ab drugs after local delivery would lead to their prolonged exposure at the disease site, thereby improving the disease condition. In this review, we illustrate the activity of clinically used anti-vascular endothelial growth factor drugs, including aflibercept (Eylea; Regeneron Pharmaceuticals, Bayer Pharma), bevacizumab (Avastin; Genentech, Novartis), and ranibizumab (Lucentis; Genentech, Novartis), in ocular diseases such as wet age-related macular degeneration and myopic choroidal neovascularization. For controlled and prolonged release of the aforementioned drugs after ocular administration, recent approaches using liposomes, hydrogels, and nanoparticles have been introduced. In addition, the evaluation methods to meet the requirements of clinically used Abs are discussed. On the basis of the findings of our review, we can suggest that an ocular delivery system can be a promising platform to overcome the limitations associated with clinically used Abs.

Original languageEnglish
Pages (from-to)373-382
Number of pages10
JournalJournal of Pharmaceutical Investigation
Volume47
Issue number5
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Antibodies
Ophthalmic Administration
Pharmaceutical Preparations
Choroidal Neovascularization
Immunoglobulin Fragments
Hydrogels
Eye Diseases
Macular Degeneration
Protein Transport
Liposomes
Nanoparticles
Vascular Endothelial Growth Factor A
Therapeutics
Monoclonal Antibodies
Antigens
Sensitivity and Specificity
Drug Liberation
Bevacizumab
aflibercept
Ranibizumab

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

@article{b0fa19bf4d034afb9c8de9137d826d53,
title = "Ocular delivery systems for the administration of antibody therapeutics",
abstract = "Antibodies (Abs) have been extensively used as a powerful tool for targeting proteins based on their immunologic functions such as antigen recognition and pathogen neutralization. In particular, monoclonal Abs (mAbs) and fragments can be promising drugs in clinics owing to their sensitivity and specificity. The controlled release of Ab drugs after local delivery would lead to their prolonged exposure at the disease site, thereby improving the disease condition. In this review, we illustrate the activity of clinically used anti-vascular endothelial growth factor drugs, including aflibercept (Eylea; Regeneron Pharmaceuticals, Bayer Pharma), bevacizumab (Avastin; Genentech, Novartis), and ranibizumab (Lucentis; Genentech, Novartis), in ocular diseases such as wet age-related macular degeneration and myopic choroidal neovascularization. For controlled and prolonged release of the aforementioned drugs after ocular administration, recent approaches using liposomes, hydrogels, and nanoparticles have been introduced. In addition, the evaluation methods to meet the requirements of clinically used Abs are discussed. On the basis of the findings of our review, we can suggest that an ocular delivery system can be a promising platform to overcome the limitations associated with clinically used Abs.",
author = "Jin, {Su Eon} and Hwang, {Sung Joo}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s40005-017-0336-6",
language = "English",
volume = "47",
pages = "373--382",
journal = "Journal of Pharmaceutical Investigation",
issn = "2093-5552",
publisher = "Springer Netherlands",
number = "5",

}

Ocular delivery systems for the administration of antibody therapeutics. / Jin, Su Eon; Hwang, Sung Joo.

In: Journal of Pharmaceutical Investigation, Vol. 47, No. 5, 01.09.2017, p. 373-382.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ocular delivery systems for the administration of antibody therapeutics

AU - Jin, Su Eon

AU - Hwang, Sung Joo

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Antibodies (Abs) have been extensively used as a powerful tool for targeting proteins based on their immunologic functions such as antigen recognition and pathogen neutralization. In particular, monoclonal Abs (mAbs) and fragments can be promising drugs in clinics owing to their sensitivity and specificity. The controlled release of Ab drugs after local delivery would lead to their prolonged exposure at the disease site, thereby improving the disease condition. In this review, we illustrate the activity of clinically used anti-vascular endothelial growth factor drugs, including aflibercept (Eylea; Regeneron Pharmaceuticals, Bayer Pharma), bevacizumab (Avastin; Genentech, Novartis), and ranibizumab (Lucentis; Genentech, Novartis), in ocular diseases such as wet age-related macular degeneration and myopic choroidal neovascularization. For controlled and prolonged release of the aforementioned drugs after ocular administration, recent approaches using liposomes, hydrogels, and nanoparticles have been introduced. In addition, the evaluation methods to meet the requirements of clinically used Abs are discussed. On the basis of the findings of our review, we can suggest that an ocular delivery system can be a promising platform to overcome the limitations associated with clinically used Abs.

AB - Antibodies (Abs) have been extensively used as a powerful tool for targeting proteins based on their immunologic functions such as antigen recognition and pathogen neutralization. In particular, monoclonal Abs (mAbs) and fragments can be promising drugs in clinics owing to their sensitivity and specificity. The controlled release of Ab drugs after local delivery would lead to their prolonged exposure at the disease site, thereby improving the disease condition. In this review, we illustrate the activity of clinically used anti-vascular endothelial growth factor drugs, including aflibercept (Eylea; Regeneron Pharmaceuticals, Bayer Pharma), bevacizumab (Avastin; Genentech, Novartis), and ranibizumab (Lucentis; Genentech, Novartis), in ocular diseases such as wet age-related macular degeneration and myopic choroidal neovascularization. For controlled and prolonged release of the aforementioned drugs after ocular administration, recent approaches using liposomes, hydrogels, and nanoparticles have been introduced. In addition, the evaluation methods to meet the requirements of clinically used Abs are discussed. On the basis of the findings of our review, we can suggest that an ocular delivery system can be a promising platform to overcome the limitations associated with clinically used Abs.

UR - http://www.scopus.com/inward/record.url?scp=85028431190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028431190&partnerID=8YFLogxK

U2 - 10.1007/s40005-017-0336-6

DO - 10.1007/s40005-017-0336-6

M3 - Review article

AN - SCOPUS:85028431190

VL - 47

SP - 373

EP - 382

JO - Journal of Pharmaceutical Investigation

JF - Journal of Pharmaceutical Investigation

SN - 2093-5552

IS - 5

ER -